Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Real-World, Interventional Study To Evaluate The Effect Of Mepolizumab On Achieving Clinical Remission In Participants With Severe Asthma

NCT06041386 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT06041386
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06041386 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Real-World, Interventional Study To Evaluate The Effect Of Mepolizumab On Achieving Clinical Remission In Participants With Severe Asthma
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Active, not recruiting
Start date
March 20, 2024
Completion date
June 14, 2028
Enrollment
336 (estimated)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

asthma